Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
46.20
-3.35 (-6.76%)
At close: Jan 8, 2025, 4:00 PM
46.00
-0.20 (-0.43%)
After-hours: Jan 8, 2025, 7:55 PM EST
Verona Pharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Verona Pharma stock have an average target of 47.67, with a low estimate of 33 and a high estimate of 74. The average target predicts an increase of 3.18% from the current stock price of 46.20.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verona Pharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $64 → $74 | Buy | Maintains | $64 → $74 | +60.17% | Jan 8, 2025 |
| Truist Securities | Truist Securities | Strong Buy Reiterates $44 → $57 | Strong Buy | Reiterates | $44 → $57 | +23.38% | Jan 8, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $64 | Buy | Maintains | $50 → $64 | +38.53% | Nov 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $36 → $42 | Strong Buy | Maintains | $36 → $42 | -9.09% | Nov 5, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $37 → $44 | Strong Buy | Maintains | $37 → $44 | -4.76% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
21.34M
Revenue Next Year
158.79M
from 21.34M
Increased by 644.06%
EPS This Year
-2.20
from -0.72
EPS Next Year
-0.41
from -2.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 29.3M | 336.7M | 495.6M | |||
| Avg | 21.3M | 158.8M | 312.6M | |||
| Low | 11.1M | 102.3M | 237.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 1,477.9% | 212.1% | |||
| Avg | - | 644.1% | 96.8% | |||
| Low | - | 379.4% | 49.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.15 | -0.15 | 0.02 | |||
| Avg | -2.20 | -0.41 | -0.23 | |||
| Low | -2.21 | -0.66 | -0.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.